Taxoprexin (DHA-paclitaxel) / Daiichi Sankyo - LARVOL DELTA

Dr. Wakelee on first trial to combine antiangiogenesis agents with immunotherapy in NSCLC (OncLive) - P3, N=NA; IMpower150; "This trial is the first to combine antiangiogenic agents with immunotherapy, says Wakelee. Results showed improved progression-free survival and overall survival (OS) with the four-drug regimen in all-comers, but also in those with EGFR mutations. Although the OS benefit wasn’t statistically significant in those patients, it was impressive, she adds."

P3 data • Video